Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SG 2000

Drug Profile

SG 2000

Alternative Names: BN-2629; NCI 694501; NSC 694501; Project P011; SJG-136; SP 2001; UP-2001

Latest Information Update: 01 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Spirogen
  • Developer National Cancer Institute (USA); Spirogen
  • Class Benzodiazepines; Cytostatic antibiotics; Pyrroles
  • Mechanism of Action DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 01 Aug 2019 Discontinued - Phase-I/II for Acute myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in USA (IV) (Spirogen pipeline, August 2019) (NCT02034227)
  • 01 Aug 2019 Discontinued - Phase-I/II for Chronic lymphocytic leukaemia (Late-stage disease, Second-line therapy or greater) in USA (IV) (Spirogen pipeline, August 2019) (NCT02034227)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top